Pancreatic ductal adenocarcinoma: metastatic disease

被引：8
作者：
Munoz Martin, A. J. [1 ]
Adeva, J. [2 ]
Martinez-Galan, J. [3 ]
Reina, J. J. [4 ]
Hidalgo, M. [5 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, C Doctor Esquerdo 46, Madrid 28007, Spain
[2] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[3] Hosp Univ Virgen Nieves, Dept Med Oncol, Granada, Spain
[4] Hosp Univ Virgen Macarena, Dept Med Oncol, Seville, Spain
[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA 02215 USA
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 12期
关键词：
Pancreatic ductal adenocarcinoma; Metastatic; Management; Treatment sequencing; Re-evaluation; NAB-PACLITAXEL; 2ND-LINE THERAPY; CANCER-PATIENTS; GEMCITABINE; OXALIPLATIN; SURVIVAL; TRIAL; GUIDELINES; UPDATE; IMPACT;
D O I：
10.1007/s12094-017-1690-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called "therapeutic sequencing" has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient's characteristics.
引用
收藏
页码：1423 / 1429
页数：7
相关论文
共 29 条
[1]  
[Anonymous], 2015, NCCN GUIDELINES MYEL
[2]  
Armstrong GT, 2015, J CLIN ONCOL, V33
[3]   Gemcitabine Plus Nab-paclitaxel as Second-line and Beyond Treatment for Metastatic Pancreatic Cancer: A Single Institution Retrospective Analysis [J].
Bertocchi, Paola ;
Abeni, Chiara ;
Meriggi, Fausto ;
Rota, Luigina ;
Rizzi, Anna ;
Di Biasi, Brunella ;
Aroldi, Francesca ;
Ogliosi, Chiara ;
Savelli, Giordano ;
Rosso, Edoardo ;
Zaniboni, Alberto .
REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) :142-145
[4]   Impact of Comorbidity and Age on Determinants Therapeutic Strategies in Advanced Pancreatic Head Cancer Patients With Obstructive Jaundices [J].
Chen, Yu-Guang ;
Pan, Hsueh-Hsing ;
Dai, Ming-Shen ;
Lin, Chin ;
Lu, Chieh-Sheng ;
Su, Sui-Lung ;
Chang, Ping-Ying ;
Huang, Tzu-Chuan ;
Chen, Jia-Hong ;
Wu, Yi-Ying ;
Chen, Yeu-Chin ;
Ho, Ching Liang .
MEDICINE, 2015, 94 (31)
[5]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[6]   Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study [J].
Demols, A ;
Peeters, M ;
Polus, M ;
Marechal, R ;
Gay, F ;
Monsaert, E ;
Hendlisz, A ;
Van Laethem, JL .
BRITISH JOURNAL OF CANCER, 2006, 94 (04) :481-485
[7]   Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors [J].
Di Maio, Massimo ;
Bria, Emilio ;
Banna, Giuseppe L. ;
Puglisi, Fabio ;
Garassino, Marina C. ;
Lorusso, Domenica ;
Perrone, Francesco .
ANTI-CANCER DRUGS, 2013, 24 (02) :99-111
[8]   Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Ducreux, M. ;
Cuhna, A. Sa. ;
Caramella, C. ;
Hollebecque, A. ;
Burtin, P. ;
Goere, D. ;
Seufferlein, T. ;
Haustermans, K. ;
Van Laethem, J. L. ;
Conroy, T. ;
Arnold, D. .
ANNALS OF ONCOLOGY, 2015, 26 :V56-V68
[9]   Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients [J].
Dykewicz, CA .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :139-144
[10]   Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study [J].
Fortune, Brett E. ;
Li, Xiaobai ;
Kosuri, Kavitha V. ;
Weatherby, Lynn M. ;
Thomas, James P. ;
Bekaii-Saab, Tanios S. .
ONCOLOGY, 2009, 76 (05) :333-337
123